Ribo Completes Recruitment for Phase 2a Trial of our FXI-targeting siRNA Drug

Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd., “Ribo”, is pleased to announce the successful completion of patient recruitment for the Phase 2a clinical trial, utilizing the world’s first and most advanced hemostasis sparing anti-thrombotic siRNA drug, targeting FXI, RBD4059.

In less than 10 months since CTA approval of the Phase 2 trial, the completion of patient recruitment marks a significant step towards Ribo’s ambition to be at the forefront of Factor XI inhibitor development. FXI inhibition has the potential to address a substantial unmet need and represents a breakthrough in anti-coagulation therapy for millions of patients. Ribo’s siRNA approach has demonstrated to achieve a robust and sustained inhibition of FXI activity with the potential for improved treatment compliance and adherence, and a low risk of drug-drug interactions.

The Phase 2a trial, NCT06717074,conducted at Ribocure Clinic in Sweden, focuses on evaluating the safety, pharmacokinetics, and pharmacodynamics of FXI-targeting siRNA, based on the RIBO-GalSTAR^TM liver targeting technology platform. This randomized, double-blind, placebo-controlled trial has involved participants with stable coronary artery disease to demonstrate proof of principle and confirm dose response in the target population.

Ribocure Clinic, the Clinical Trial Unit (CTU) of Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd., is located at GoCo Health Innovation City in Mölndal, Sweden. The CTU invites trial participants to take part in clinical trials conducted by experienced and highly trained medical research staff. Specializing in advanced Phase 2 trial endpoints in cardiovascular, pulmonary, renal, and liver areas, the CTU employs advanced imaging and functional assessments.

Dr. Li-ming Gan, CEO of Ribocure Pharmaceuticals AB, commented, “Our Clinic’s setup integrates cutting-edge concepts in clinical trial excellence, including a precision medicine approach to match the right patients with the right trials. I am impressed by the swift transition from approval to the recruitment of the last patient, marking a significant milestone in our pursuit of high-quality Proof of Principle studies.”